$-0.59
(Market cap
$380,567 Mln
Revenue (TTM)
$62,819 Mln
P/E Ratio
105.1
P/B Ratio
50.5
Div. Yield
3.2 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.6 %
-
ROCE
6.2 %
-
Industry P/E
30.2
-
EV/EBITDA
26.2
-
Debt to Equity
-9.8
-
Book Value
$--
-
EPS
$2.1
-
Face value
--
-
Shares outstanding
1,766,792,821
10 Years Aggregate
CFO
$142,983.00 Mln
EBITDA
$134,251.00 Mln
Net Profit
$64,606.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AbbVie (ABBV)
| -7.1 | 2.8 | -8.5 | 14.1 | 16.7 | 13.6 | 13.0 |
|
BSE Sensex
| -11.8 | -2.9 | -8.2 | -8.4 | 6.1 | 7.5 | 10.8 |
|
S&P 100
| 9.4 | 5.9 | 13.0 | 31.1 | 24.1 | 14.8 | 15.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
AbbVie (ABBV)
| 28.6 | 14.5 | -4.1 | 19.4 | 32.4 | 27.7 | 1.5 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AbbVie (ABBV)
|
212.3 | 380,567.2 | 62,819.0 | 3,639.0 | 14.1 | -- | 105.1 | 50.5 |
| 325.6 | 181,768.4 | 37,238.0 | 7,800.0 | 29.1 | 82.9 | 23.4 | 19.7 | |
| 54.4 | 116,765.6 | 48,482.0 | 7,275.0 | 21.6 | 37.7 | 16 | 5.9 | |
| 1,066.6 | 965,684.6 | 72,249.5 | 25,275.0 | 43.6 | 91.9 | 38.5 | 31.0 | |
| 128.2 | 166,904.2 | 29,734.0 | 9,216.0 | 39.5 | 40.9 | 18.3 | 7.1 | |
| 223.4 | 556,765.2 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 26.7 | 6.9 | |
| 115.9 | 296,971.7 | 65,593.0 | 8,935.0 | 30.5 | 18.3 | 33.9 | 6.5 | |
| 143.4 | 288,350.8 | 56,053.0 | 13,533.8 | 30.3 | 32.7 | 21.7 | 7.5 | |
| 25.4 | 149,382.4 | 63,315.0 | 7,491.0 | 17.0 | 8.1 | 20 | 1.7 | |
| 42.5 | 104,535.9 | 47,354.0 | 7,555.0 | 19.6 | 10.3 | 19 | 1.2 |
Shareholding Pattern
View DetailsAbout AbbVie (ABBV)
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat... inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Read more
-
Chairman & CEO
Mr. Richard A. Gonzalez
-
Executive Chairman
Mr. Richard A. Gonzalez
-
Headquarters
North Chicago, IL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for AbbVie (ABBV)
What is the current share price of AbbVie Inc (ABBV) Today?
The share price of AbbVie Inc (ABBV) is $212.34 (NYSE) as of 02-Jun-2026 12:47 EDT. AbbVie Inc (ABBV) has given a return of 16.75% in the last 3 years.
What is the current PB & PE ratio of AbbVie Inc (ABBV)?
The P/E ratio of AbbVie Inc (ABBV) is 105.07 times as on 29-May-2026, a 248 premium to its peers’ median range of 30.20 times.
The P/B ratio of AbbVie Inc (ABBV) is 50.46 times as on 29-May-2026, a 754 premium to its peers’ median range of 5.91 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
95.92
|
-125.57
|
|
2024
|
73.65
|
93.66
|
|
2023
|
56.47
|
26.41
|
|
2022
|
24.28
|
16.62
|
|
2021
|
20.86
|
15.60
|
What is the 52 Week High and Low of AbbVie Inc (ABBV)?
The 52-week high and low of AbbVie Inc (ABBV) are Rs 244.81 and Rs 181.73 as of 02-Jun-2026.
What is the market cap of AbbVie Inc (ABBV)?
AbbVie Inc (ABBV) has a market capitalisation of $ 380,567 Mln as on 29-May-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in AbbVie Inc (ABBV)?
Before investing in AbbVie Inc (ABBV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.